8-K: FOXO Technologies Boosts Authorized Shares Fivefold

FOXO Technologies' majority stockholder approved a significant increase in authorized Class A Common Stock from 500 million to 2.5 billion shares.

Summary

• The majority stockholder of FOXO Technologies Inc., Rennova Health, Inc. (controlled by the Company's CEO), approved an amendment to the Certificate of Incorporation.
• The amendment increases the authorized shares of Class A Common Stock from 500,000,000 to 2,500,000,000 shares, par value $0.0001 per share.
• The majority stockholder held approximately 56.71% of the Company's voting rights as of the Record Date, September 10, 2025.
• The effective date of the Authorized Increase will be determined by the Board of Directors at its sole discretion, without further stockholder approval, any time before March 31, 2026.
• The Company will file a preliminary Information Statement on Schedule 14C and subsequently mail a definitive Information Statement to stockholders, with the approved actions becoming effective 20 days after mailing.

Sentiment

Score: 5

Explanation: The increase in authorized shares is a neutral corporate action that provides strategic flexibility for future capital raises or corporate actions. While it enables potential growth and financial stability, it also introduces the risk of significant shareholder dilution, which could be perceived negatively by existing investors. The concentration of voting power with the CEO's controlled entity is also a factor.

Positives

• Provides FOXO Technologies with significant flexibility to raise capital through equity offerings in the future.
• Enables the company to pursue strategic initiatives, such as mergers, acquisitions, or equity-based compensation plans, without immediate need for further stockholder approval for share authorization.

Negatives

• The substantial increase in authorized shares creates the potential for significant future dilution of existing shareholders' ownership and voting power.
• The approval by a majority stockholder controlled by the CEO highlights concentrated control, potentially limiting the influence of other shareholders.

Risks

• **Shareholder Dilution:** The issuance of a large number of new shares could significantly dilute the ownership percentage and earnings per share of current stockholders.
• **Stock Price Impact:** The prospect of substantial future share issuance may exert downward pressure on the company's stock price.
• **Concentration of Control:** The majority stockholder, controlled by the CEO, holds significant voting power, which could lead to decisions that may not align with the interests of all minority shareholders.

Future Outlook

The increase in authorized shares provides FOXO Technologies with enhanced flexibility for future capital formation and strategic corporate actions. The Board of Directors retains discretion over the timing of the share increase's effectiveness, allowing for opportunistic use of the expanded share pool.

Management Comments

• Seamus Lagan, Chief Executive Officer, duly authorized the signing of this report on behalf of FOXO Technologies Inc.

Industry Context

Increasing authorized shares is a common corporate governance action, particularly for growth-oriented companies or those seeking to strengthen their balance sheet. It provides a company with the necessary flexibility to raise capital through equity, facilitate mergers and acquisitions, or implement equity compensation plans, aligning with broader industry trends of companies preparing for future strategic moves.

Comparison to Industry Standards

• The action of increasing authorized shares is a standard corporate governance practice across various industries, enabling companies to maintain flexibility for future capital needs or strategic transactions.
• A fivefold increase in authorized shares, while substantial, is not unprecedented, especially for companies with low share prices or significant growth ambitions requiring substantial capital.
• The filing does not provide specific comparable companies, projects, or results to benchmark this particular action against industry peers.

Corporate Governance

Related Party Transactions

• Rennova Health, Inc., an entity controlled by FOXO Technologies Inc.'s CEO, acted as the Majority Stockholder, approving the amendment by written consent.

Stakeholder Impact

• **Shareholders:** Face potential dilution of their ownership percentage and voting rights if new shares are issued, but the company gains flexibility for future growth initiatives that could ultimately benefit long-term value.
• **Management:** Gains significant flexibility in capital structure management and strategic decision-making regarding future equity issuance.

Next Steps

• File a preliminary Information Statement on Schedule 14C with the U.S. Securities and Exchange Commission.
• Mail the definitive Information Statement on Schedule 14C to stockholders of record as of September 10, 2025.
• The approved actions will become effective 20 days after the mailing of the definitive Information Statement.
• The Board of Directors will determine the effective date of the Authorized Increase at its sole discretion, any time before March 31, 2026.

Key Dates

Recommendation

The approval to significantly increase authorized shares provides FOXO Technologies with crucial flexibility for future capital raises or strategic transactions. While this is a necessary step for growth or financial stability, it also introduces the risk of substantial dilution for existing shareholders. The concentration of voting power with the CEO's controlled entity is also a factor. Investors should hold and monitor the company's specific plans for utilizing these newly authorized shares and assess the impact on per-share value before making further investment decisions.

Keywords

FOXO Technologies, Authorized Shares, Stock Dilution, Corporate Governance, SEC Filing, Class A Common Stock, Capital Raise, Rennova Health, Amendment to Charter